Головна » Файли » 2014 » 4 (124) |
08.10.2014, 18:53 | |
Резюме Резюме Summary Рецензент: д.мед.н., проф. В.О. Тєрьошин УДК 616.12 - 008.331.1 - 092 - 085: 616.379 - 008.64 ДУ «Національний інститут терапії ім. Л.Т.Малої НАМН України » ГУ «Национальный институт терапии им. Л.Т. Малой НАМНУ» (Харьков) GI «L. T. Mala National Therapy Institute of the NAMS of Ukraine» (Kharkov) tatstarchenko@mail.ru, snkoval@inbox.ru, kostyayu@ukr.net, d.miloslavsky@gmail.com, shkapovl@gmail.com Arterial hypertension and diabetes mellitus are among the most common diseases in the world. Important role in the progression of organ abnormalities due to hypertension belongs insulin resistance, oxidative stress, microalbuminuria (MAU) that significantly aggravate course of essential hypertension (EH) in combination with type 2 diabetes (T2D). Therefore, an important aspect of prevention of damage to target organs in these patients is timely combined pharmacological correction. Objective. The aim of this study was to investigate the indicators of insulin resistance, oxidative stress and MAU in patients with EH and T2D in the dynamics of treatment. Materials and methods. The examination involved 33 patients with EH without T2D and 24 hypertension patients with T2D. All patients treated with olmesartan (20-40 mg per day) and lercanidipine (10-20 mg per day). The patients with dyslipidemia were treated with atorvastatin (10-20 mg in the evening) and hypertension patients with T2D treated with metformin (850-1000 mg per day) additionally. The course of treatment was 3 months. Results. The therapy caused a significant antihypertensive effect. In patients with EH and T2D target blood pressure was achieved in 79% and in hypertension patients without diabetes - in 82%. In the patients in both groups were observed positive changes in carbohydrate and lipid metabolism. The levels of the malondialdehyde (MDA) were significant higher in patients with EH and T2D compared as the control group and hypertension patients without diabetes. MAU was observed in 40% of patients without diabetes and in 68% of cases in hypertension patients with T2D. We analyzed the levels of MDA depending from presence of MAU. In hypertension patients with T2D and MAU the levels of MDA were (17,8±1,8) umol/l and without MAU - (12,84±2,81) umol/l (р<0,001). If the patients with EH without T2D had MAU, they have had significant higher levels of MDA in comparison with control group and hypertension patients without MAU. Similar dynamics of this indicator of lipid peroxidation was detected when EH associated with T2D. These data may indicate that the development of endothelial dysfunction leads to a more severe activation of oxidative stress. Based on the fact that the MAU is one of the indicators of subclinical damage of target organs, it should be noted the significant role the of free radical oxidation in increasing the damaging effects of MAU. We analyzed the levels of MDA in the dynamics of combined therapy. The blood levels of MDA in both groups of hypertension patients with T2D and without it significantly decreased after treatment, without reaching normal values and demonstrating preservation of high level processes of lipid peroxidation. Conclusion. The use of combination treatment with olmesartan and lercanidipine with antidiabetic and lipid-lowering therapy leads to a significant antihypertensive effect, improves lipid metabolism and manifestations of oxidative stress in patients with EH and T2D and without it, which reduces damage to target organs in these patients. Литература 1. Сиренко Ю.Н. Гипертоническая болезнь и артериальные гипертензии / Ю.Н. Сиренко – Донецк: Изд. Заславский, 2011. - 352 с. References 1. Sirenko, Ju.N. (2011), Gipertonicheskaja bolezn' i arterial'nye gipertenzii [Essential hypertension and arterial hypertensions], Izdatel'stvo Zaslavskij, Donetsk, Ukraina. 2. Belovol, A.N. Shkol'nik, V.V. and Nemcova, V.D. (2012), “New approaches to the treatment of patients with essential hypertension and diabetes mellitus type 2”, Ukrainskij terapevticheskij zhurnal, vol. 2, pp. 32-38. 3. Manishhenkova, Ju.A. Shkala, L.V. Dudich, T.I. Litvinova, M.I. and Ivanova, M.V. (2013), “Oxidative stress in patients with type 2 diabetes, combined with acute exacerbation of chronic pyelonephritis”, Mezhdunarodnyj jendokrinologicheskij zhurnal, vol. 3, pp. 19-22. 4. Leksina, K.S. Timofeeva, N.Ju. Zadionchenko, V.S. Shehjan, G.G. and Aldushina, K.A. (2007), “Oxidative stress and the possibility of its correction with ACE inhibitors in patients with myocardial infarction combined with type 2 diabetes”, Racional'naja farmakoterapija v kardiologii, vol. 2, pp. 53-58. 5. Kadykova, O. I. (2012), “The role of hormones in adipose tissue genesis of insulin resistance in patients with hypertension and diabetes mellitus type 2”, Mezhdunarodnyj medicinskij zhurnal, vol. 4, pp. 54-57. 6. Baryshnikova, G.A. Chorbinskaja, S.A. and Stepanova, I.I. (2014), “Calcium antagonist lercanidipine in hypertension”, Kardiosomatika, vol. 1, pp. 9-15. 7. Folli, F. Corradi, D. Fanti, P. and Davalli, A. (2011), “The role of oxidative stress in the pathogenesis of type 2 diabetes mellitus micro- and macrovascular complications: avenues for a mechanistic-based therapeutic approach”, Current Diabetes Review, vol. 7(5), pp. 313-324. 8. Basi, S. Fesler, P. Mimran, A. and Lewis, J., (2008) “Microalbuminuria in Type 2 Diabetes and Hypertension - A marker, treatment target, or innocent bystander?”, Diabetes Care, vol. 31, pp. S194-S201. 9. Bacanu, E.V. Bacanu, M.E. and Botez, C. (2011), “Microalbuminuria in essential hypertension of patients whith or without type 2 diabetes”, Proc. Rom. Acad., Series b, pp.145-154. 10. Yang, H.I. Jin, X. Kei Lam, C.W. and Yan, S.K. (2011), “Oxidative stress and diabetes mellitus”, Clin. Chem. Lab. Med., vol. 49, no. 11, pp. 1773-1782. 11. Brunner, H.R. (2002), “The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview”, J. Hum. Hypertens., vol.16, suppl. 2, pp. S13–16. 12. Fiorentino, T.V. Prioletta, A. Zuo, P. and Folli, F. (2013), “Hyperglycemia-induced oxidative stress and its role in diabetes mellitus related cardiovascular diseases”, Curr. Pharm. Des., vol.19, no. 32, pp. 5695-5703. | |
Переглядів: 755 | Завантажень: 0 | |
Всього коментарів: 0 | |